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Introduction
============

The identification of novel molecular targets for cancer therapy has led to a paradigm shift in drug development, with more emphasis placed now on small molecules that can effectively inhibit signalling pathways deregulated in cancer cells. Of the many survival pathways activated by cancer cells, hypoxic cell signalling has attracted significant interest for a number of years, based on the assumption that normal tissues do not experience the same extreme variations in oxygen levels present in the tumour microenvironment. Cancer cells are exposed to a gradient of oxygen levels that fluctuate in time and space, which trigger the activation of survival pathways that are not usually induced in normal tissues and that can be potentially targeted for therapeutic purposes \[[@b1]\].

The discovery of hypoxia inducible factor (HIF)-1 in the early 1990s provided a molecular target associated with intratumour hypoxia that could be used for the development of novel cancer therapeutics \[[@b2]\]. Despite the intrinsic challenges associated with the discovery and development of pharmacological inhibitors of transcription factors, more so in the absence of structural information that could facilitate drug design, many academic groups and pharmaceutical companies have attempted to identify HIF-1 inhibitors \[[@b3]--[@b6]\]. For the most part, efforts have been based on high throughput screening assays aimed at identification of inhibitors of HIF-1 expression and/or transcriptional activity \[[@b4]\]. After several years of attempts and many HIF-1 inhibitors described in the literature, there are several conclusions that can be drawn and considerations that can be made, which might help in shaping future directions in this field.

The common denominator of most, if not all, HIF-1 inhibitors described so far is the lack of specificity, which indicates the fact that they inhibit multiple targets and that HIF-1 inhibition cannot be easily separated from other activities exerted by these agents. This feature of HIF-1 inhibitors may have hampered efforts in validating HIF-1 as a target using pharmacological approaches; nevertheless HIF-1 inhibitors they may still have potential applications for therapeutic purposes. A challenge that HIF-1 inhibitors must face to be 'validated' as potential therapeutic tools is the evidence that they inhibit the intended target in relevant *in vivo* models and more so in patients with cancer. Indeed, inhibition of HIF-1 expression and/or activity in cell culture is hardly predictive of their potential usefulness as therapeutic agents. However, validation of HIF-1 inhibitors in pre-clinical models is hindered by the lack of established biomarkers that can be consistently associated with HIF-1 inhibition in tumour tissue. Different end-points have been measured to assess HIF-1 inhibition in published studies, including but not limited to IHC and/or Western blot analysis of HIF-1α protein expression, mRNA expression of HIF-1 target genes and more indirect, surrogate end-points of HIF inhibition, *e.g.* angiogenesis and microvessels density. Despite these challenges, efforts to validate HIF-1 inhibitors in appropriate *in vivo* models are essential to move these potential therapeutic agents to the clinical setting. This is even more relevant in light of the potential lack of antitumour activity of HIF-1 inhibitors used as single agents. In fact, antitumour activity cannot be and should not be used as a surrogate end-point for the validation of HIF-1 inhibition, as it is conceptually difficult to envision how HIF-1 inhibition alone may be associated with dramatic tumour shrinkage in xenograft models in which HIF-1 expression in tumour tissue is heterogeneous and focal in nature.

Even more challenging is, of course, to generate evidence of HIF-1 inhibition in the clinical setting. However, this is a necessary path for the validation of HIF-1 inhibitors in early clinical trials and for the development of this strategy in combination approaches, which appears to be a more promising avenue for the application of HIF-1 inhibitors.

In this review, we will discuss more in detail HIF-1 inhibitors that have been recently described, referring to previously published reviews for a more systematic description of HIF-1 inhibitors \[[@b5], [@b6]\]. In particular, we will emphasize those agents for which validation of HIF-1 inhibition in pre-clinical models has been provided and/or agents that are in early clinical development. It is hoped that results of ongoing clinical trials with HIF-1 inhibitors may provide in the near future sufficient information that should aid in the design of future strategies aimed at targeting hypoxic cell signalling.

Mechanisms of action of HIF-1 inhibitors
========================================

An ever increasing number of agents are constantly being reported that inhibit HIF-1α expression and/or activity. We will attempt to discuss these agents based on their putative mechanism of action ([Fig. 1](#fig01){ref-type="fig"}), which could provide some useful insights for their clinical development. It should also be noted that the information published so far relates for the most part to HIF-1α, although many of these agents may also affect HIF-2α. Both subunits are potential targets of small molecule inhibitors and no clear selectivity, capable of discriminating between inhibition of HIF-1α or HIF-2α, has been so far convincingly demonstrated.

![Proposed mechanisms of action of HIF-1 inhibitors.](jcmm0013-2780-f1){#fig01}

According to their putative mechanism of action and although this is an obviously simplified classification, HIF inhibitors could be tentatively divided in agents that modulate: HIF-1α mRNA expressionHIF-1α protein translationHIF-1α protein degradationHIF-1α DNA binding andHIF-1α transcriptional activity.

Inhibitors of HIF-1α mRNA expression
====================================

HIF-1α accumulation is controlled primarily at the level of protein degradation or protein translation and most of the HIF-1α inhibitors identified so far target these pathways. However, it has also been suggested that, under hypoxic conditions, levels of HIF-1α mRNA may be a limiting factor affecting the rate of protein translation \[[@b7]\] and it is presumable that small molecule inhibitors might affect HIF-1α mRNA expression \[[@b8]\] and as a consequence the rate of HIF-1 translation.

An interesting approach that might add specificity to HIF-1α inhibition is the use of an antisense oligonucleotide targeting HIF-1α (EZN-2698) \[[@b9]\]. EZN-2968 is highly specific and binds HIF-1α mRNA with high affinity causing its down-regulation and consequent reduction of HIF-1α protein levels, both *in vitro* and *in vivo*. Treatment with EZN-2968 results in tumour cell growth inhibition, down-regulation of HIF-1α target genes and impaired ability of HUVEC cells to form tubes *in vitro*. *In vivo*, EZN-2968 administration decreased endogenous HIF-1α and vascular endothelial growth factor (VEGF) mRNA levels in the liver of normal mice and showed antitumour activity in xenograft models of human prostate cancer (DU145). Preliminary results of ongoing phase I clinical trials in patients with advanced solid tumours indicate that EZN-2968 can be given safely and that potential activity has been observed in one patient with metastatic renal cell carcinoma (RCC). Future studies will be required to address a main limitation of antisense oligonucleotide approaches, which is the delivery to tumour tissues.

Another agent that appears to affect HIF-1α mRNA expression is aminoflavone. AF is a ligand of the aryl-hydrocarbon receptor (AhR) and is currently in phase I clinical trials in patients with metastatic cancer. Based on the notion that AhR dimerizes with HIF-1β, it was interesting to test whether pharmacological activation of the AhR pathway using AF might affect HIF-1α levels. Results of these studies have shown that AF does indeed inhibit HIF-1α accumulation, although in an AhR-independent fashion. The proposed mechanism of HIF-1 inhibition by AF is modulation of HIF-1α mRNA expression, although the exact mechanism remains to be fully elucidated.

Inhibitors of HIF-1α protein translation
========================================

Although the mechanism(s) underlying hypoxic regulation HIF-1α translation are still poorly understood, several agents have been described that may affect the rate of HIF-1α protein synthesis, including but not limited to inhibitors of topoisomerase I and II \[[@b10]--[@b12]\], receptor tyrosine kinase \[[@b13]--[@b15]\], cyclin-dependent kinase \[[@b16]\], oncogenic pathways \[[@b17]--[@b21]\], thioredoxin reductase \[[@b22]\], activators of p53 \[[@b23]\] and microtubule disrupting agents \[[@b24]\].

One of the first agents described that may affect HIF-1α protein translation is topotecan, an FDA approved chemotherapeutic agent currently used as second line therapy for patients with small cell lung cancer or ovarian cancer. Topotecan was originally identified at the National Cancer Institute in a high throughput screen using a cell-based assay of HIF-1 transcriptional activity \[[@b25]\]. Topotecan is a camptothecin analogue that poisons topoisomerase I by inducing the formation of stable Top1-DNA cleavage complexes, which in the presence of DNA replication generate double strand DNA breaks and cytotoxicity. Interestingly, topotecan inhibited HIF-1α translation by a Top1-dependent but DNA damage-independent mechanism, suggesting that cytotoxicity and HIF-1α inhibition could be mechanistically distinguished \[[@b26]\]. Indeed, daily low dose administration of topotecan in a mouse xenograft glioma model caused inhibition of HIF-1α protein expression, angiogenesis and tumour growth \[[@b27]\]. More recently, it has been shown that administration of daily topotecan in combination with the anti-VEGF antibody bevacizumab exerts synergistic antitumour activity in xenograft models, providing a rationale for clinical development of this combination strategy \[[@b28]\]. A pilot study ongoing at NCI in which daily oral topotecan is given to patients with metastatic refractory cancers should provide evidence as to whether this agents is able to affect HIF-1 signalling in tumour tissue (<http://clinicaltrials.gov/ct2/show/NCT00182676>).

The ability to inhibit HIF-1α protein translation appears to be shared by all the agents that inhibit Top1. Because topotecan has a short half-life when administered to patients, it is conceivable that other topoisomerase 1 inhibitors with more favourable pharmacokinetics may be more suitable for chronic suppression of the HIF-1 pathway. In this regard an interesting agent is EZN-2208, a PEGylated form of SN38, the active component of CPT-11 (Irinotecan Pfitzer, New York, NY, USA; Yakult Honsha, Tokyo, Japan), characterized by improved pharmacokinetics and by remarkable antitumour activity in pre-clinical models of solid tumours and lymphomas, including CPT-11-resistant tumours \[[@b29]\]. The demonstrated activity of EZN-2208 in CPT-11 refractory tumours could be potentially explained by the ability of this agent to inhibit HIF-1α accumulation, thus acting on the tumour microenvironment rather than only on cancer cells \[[@b30]\]. EZN-2208 is currently in phase I clinical trials and phase II as well as combination studies are being planned.

Cardiac glycosides are another class of agents that have been recently reported to affect HIF-1α protein translation. In particular digoxin was identified as a potent inhibitor of HIF-1 activity in a cell-based screen of a chemical library of FDA approved agents \[[@b31]\]. Digoxin inhibited the translation of HIF-1α by an mTOR-independent mechanism and showed antitumour activity in xenograft models. Interestingly, digoxin inhibited tumour growth in established PC3 and P493-Myc tumour xenografts, yet did not affect the growth of xenografts expressing a constitutively active form of HIF-1α, implicating HIF-1 in the antitumour activity of digoxin. Interestingly, digoxin, which is routinely used for the treatment of heart failure and arrhythmias, is currently being tested in a phase I clinical trial as a potential anticancer agent. Consistent with these results, fractionation of an organic solvent extract of the plant Crossosoma bigelovii led to the discovery of a new strophanthidin glycoside that also inhibited HIF-1 transcriptional activity \[[@b32]\]. Whether cardiac glycosides may effectively be used to inhibit HIF-1 in cancer patients, in the absence of unacceptable adverse events, remains to be established.

Another HIF-1 inhibitor currently in phase I clinical trials in patients with advanced metastatic cancer is PX-478. This agent showed remarkable antitumour activity in a variety of human tumour xenograft models, which seemed to correlate with levels of expression of HIF-1α\[[@b33]\]. PX-478 inhibited constitutive and hypoxia-induced HIF-1α expression in a pVHL and p53 independent fashion. The inhibition seems to occur at multiple levels, since three different mechanisms have been proposed that might contribute to the decrease of HIF-1α accumulation. Indeed, it has been suggested that PX-478 inhibits HIF-1α deubiquitination, leading to increased degradation of polyubiquitinated HIF-1α, reduces HIF-1α mRNA expression and also affects HIF-1α translation \[[@b34]\]. Results of an ongoing phase I trial should be available in the near future and might provide interesting information regarding antitumour activity and modulation of HIF-1α levels in cancer patients.

A signalling pathway that has been implicated in growth factor-dependent induction of HIF-1α translation is mTOR \[[@b35], [@b36]\]. However, mTOR and global protein synthesis are inhibited under severe hypoxia, thus the contribution of these pathways to HIF-1α translation under hypoxic conditions is still poorly understood \[[@b37]\]. Several mTOR inhibitors, including temsirolimus and everolimus that are FDA approved agents for the treatment of renal cancer, have been shown to inhibit HIF-1α\[[@b38]--[@b40]\]. Clinical trials have demonstrated efficacy of these agents in the treatment of RCC \[[@b41]\]. Up to 75% of sporadic clear cell RCCs are VHL-deficient therefore HIF-α is stabilized under normoxic conditions \[[@b42]\]. In this context mTOR may contribute to increase HIF-α protein levels and this might contribute to the efficacy of mTOR inhibitors in RCC \[[@b43]\]. In a phase III clinical study, temsirolimus as a single agent significantly improved overall survival of patients with advanced RCC and poor prognosis compared with IFN-α treatment \[[@b44]\]. The administration of everolimus to patients with metastatic RCC that progressed after VEGF-targeted therapies resulted in a prolongation of progression-free survival compared with placebo in a randomized phase III clinical trial \[[@b45]\]. Clinical trials are ongoing to evaluate the potential of mTOR inhibitors, as single agents or in combination studies, for the treatment of other solid malignancies. Whether HIF-1α inhibition may contribute to the therapeutic activity of this class of agents in malignancies other than renal cancer remains to be established.

Inhibitors that affect HIF-1α degradation pathway
=================================================

Hsp90 is a molecular chaperone that controls the folding and regulates the function of different client proteins, including receptor tyrosine kinases, serine/threonine kinases, transcription factors and activated oncoproteins \[[@b46]\]. HIF-1α protein stability is also affected by its interaction with Hsp90. In the presence of Hsp90 inhibitors HIF-1α undergoes VHL-independent proteasomal degradation \[[@b47]\]; moreover HIF-1α heterodimers may not acquire the proper conformation and fail to recruit cofactors important for HIF-1-mediated transcriptional activity \[[@b48]\]. The development of Hsp90 inhibitors started with the discovery of the natural product galdanamycin, a benzoquinone ansamycin antibiotic that inhibits Hsp90 by competing with the ATP binding site. Galdanamycin was found to induce HIF-1α degradation under both hypoxic and normoxic conditions in several cell lines \[[@b49]\]. The first Hsp90 inhibitors to enter clinical trials were 17-AAG and 17-DMAG and currently, a large number of second generation Hsp90 inhibitors are in clinical development as anticancer agents \[[@b50]\]. However, given the range of client proteins that may be affected by Hsp90 inhibition, it is difficult to determine whether and to what extent their antitumour activity may be related to HIF inhibition, more so in the absence of clinical trial aimed at assessing the specific effects of Hsp90 inhibition on HIF-1 signalling pathway.

Histone deacetylase inhibitors have also been implicated in the regulation of HIF-1 activity by several potential mechanisms, including induction of HIF-1α protein degradation and regulation of HIF-1 transcriptional activity \[[@b51]\]. Although a direct role of acetylation in the regulation of HIF-1α protein remains controversial, recent evidence indicates that Sirtuin 1 (Sirt1), a redox-sensing deacetylase, selectively stimulates activity of HIF-2α during hypoxia \[[@b52]\]. Histone deacetylase inhibitors are currently being evaluated in a number of solid tumours as single agents or in combination studies and inhibition of HIF-1 should be considered as a potential mechanism contributing to their activity.

Inhibitors of HIF-1 binding to DNA
==================================

Inhibition of HIF-1 DNA binding to the hypoxia responsive element (HRE), a step required for induction of transcription, is also a potential mechanism by which small molecules may inhibit HIF-1 activity \[[@b53]--[@b55]\].

Proof of principle that this mechanism may effectively inhibit HIF-1 transcriptional activity was provided by the identification of echinomycin, a cyclic peptide of the family of quinoxaline antibiotics originally isolated from Streptomyces echinatus, which was known to bind DNA in a sequence-specific fashion. Echinomycin was shown in chromatin immunoprecipitation experiments to inhibit HIF-1, but not AP-1 or NF-κB, binding to DNA, providing evidence of a fairly selective inhibition based on recognition of DNA sequences \[[@b56]\]. Echinomycin clinical development was halted in the late 1980s following extensive testing as cytotoxic agent in phase I-II trials, which failed to show significant activity.

More recently, anthracyclines were found to inhibit HIF-1 activity \[[@b57]\]. Anthracyclines exert their cytotoxic activities by a number of different mechanisms, including DNA intercalation, and are among the most effective chemotherapeutic agents used to treat a wide range of cancers. Recent evidence indicated that doxorubicin (DXR) and daunorubicin (DNR) inhibit HIF-1α transcriptional activity by blocking its binding to the HRE sequence. Administration of DXR or DNR to mice bearing human prostate cancer xenografts significantly inhibited tumour growth and vascularization, along with a decrease of circulating angiogenic cells (CAC). The mobilization of CACs in the bloodstream was shown to be mediated by HIF-1-induced genes encoding pro-angiogenic cytokines, which were significantly down-regulated in anthracycline-treated mice. These results raise the possibility that metronomic administration of anthracyclines may exert antitumour activity by inhibiting HIF-1 and angiogenesis and that HIF-1 inhibition may be one of the potential mechanisms contributing to the activity of metronomic chemotherapy.

Inhibitors of HIF-1α transcriptional activity
=============================================

Chetomin was originally identified as an inhibitor of HIF-1 transcriptional activity by interfering with the interaction of HIF-1α with the co-activator p300 \[[@b58]\]. However, because of toxicity the development of chetomin has not been further pursued.

Inhibition of the proteasome leads to normoxic accumulation of HIF-1α\[[@b59]\]. Paradoxically, HIF-1α that accumulates in the presence of proteasome blockade is transcriptionally inactive \[[@b60]\]. Bortezomib (PS-341) is a proteasome inhibitor FDA approved for treatment of patients with multiple myeloma and patients with mantle cell lymphoma who had received at least one prior therapy \[[@b61], [@b62]\]. Interestingly, the antitumour activity of bortezomib may correlate with its ability to repress HIF-1α transcriptional activity \[[@b63]\]. At low nanomolar concentrations bortezomib was able to impair the p300-HIF-1α interaction, by enhancing the binding of FIH to HIF-1α\[[@b64]\]. FIH is a dioxygenase that hydroxylates Asn803 in the C-terminal transactivation domain of HIF-1α, thus preventing the recruitment of the co-activator p300. Interestingly, the concentrations of bortezomib able to inhibit HIF-1α activity are much lower than those required to impair proteasome function, suggesting that the mechanism of HIF inhibition by bortezomib may be independent from proteasome inhibition \[[@b65]\].

Conclusions
===========

Significant progress in our understanding of the molecular mechanism(s) underlying intratumour hypoxia has fuelled interest in developing strategies targeting hypoxic cell signalling for cancer therapy. In addition, therapy-induced hypoxia, which may be caused by anti-VEGF therapies, has provided challenges but also opportunities for the development of combination strategies incorporating HIF-1-targeting agents. The excitement for innovative approaches targeting previously poorly characterized pathways triggered by hypoxia in the tumour microenvironment has been so far tempered by the lack of specific and effective small molecules that may be thought of as 'gold standard' for HIF-1 inhibition. Nevertheless, validation of available small molecules in pre-clinical models and more importantly in early clinical trials may provide a unique opportunity for the pharmacological inhibition of hypoxia-induced pathways that can be clinically exploitable. Efforts should be devoted to implementing well-designed, pharmacodynamic-based early clinical trials of promising HIF-1 inhibitors to validate their activity and identify agents that can be used in combination strategies.
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